Bio-Techne vs Pfizer
Side-by-side comparison of AI visibility scores, market position, and capabilities
Minneapolis life science tools (NASDAQ: TECH) at $1.19B FY2024 revenue; Q2 FY2025 9% organic growth, R&D Systems cytokines/antibodies + RNAscope spatial biology (500K+ products) competing with Thermo Fisher for biopharma reagents.
About
Bio-Techne Corporation is a Minneapolis, Minnesota-based life sciences tools company — publicly traded on NASDAQ (NASDAQ: TECH) as an S&P 500 Health Care component — developing, manufacturing, and selling biological reagents, proteins, antibodies, assay kits, analytical instruments, and spatial biology tools for pharmaceutical drug discovery, bioprocessing, academic research, and clinical diagnostics through approximately 3,000 employees across 34 global locations with an annual revenue of $1.19 billion in fiscal year 2024. In Q2 fiscal 2025, Bio-Techne reported organic revenue growth of 9% to $297 million, demonstrating recovery from the funding-constrained biotech environment of 2023-2024. The company operates through two segments: Protein Sciences (approximately 75% of revenue, including the R&D Systems portfolio of 500,000+ life science products — cytokines, growth factors, antibodies, ELISAs, and recombinant proteins — as well as ProteinSimple analytical instruments and Tocris Bioscience chemical biology tools) and Diagnostics and Genomics (approximately 25%, including Advanced Cell Diagnostics' RNAscope technology for gene expression visualization in intact tissue and Lunaphore's COMET spatial biology automation platform acquired in 2023). Bio-Techne launched approximately 800 new products in fiscal 2024 and maintains a catalog of 6,000+ recombinant proteins spanning 35 species. The company has a market capitalization of approximately $9.59 billion.
Global biopharma with $63.6B FY2024 revenue; $43B Seagen ADC acquisition rebuilds post-COVID pipeline; patent cliff 2026-2028 for Eliquis; activist Starboard Value pushing restructuring.
About
Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The company trades on NYSE (PFE) and reported $63.6 billion in total revenues for FY2024, normalizing from pandemic highs of $100 billion-plus in 2021-2022 driven by Comirnaty COVID-19 vaccine revenues with BioNTech and Paxlovid COVID antiviral sales. CEO Albert Bourla has led a strategic pivot to reset the company's long-term growth profile, anchored by the landmark $43 billion acquisition of Seagen in December 2023, adding a world-class antibody-drug conjugate (ADC) oncology pipeline including Padcev, Tukysa, Adcetris, and Tivdak.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.